联邦制药：UBT251 II 期数据惊艳，催化全球潜力-20260227

Investment Rating - The report maintains a "Buy" rating for the company [6][5]. Core Insights - The UBT251 Phase II weight loss data is impressive, showing a higher weight loss rate at lower doses compared to Eli Lilly's retatrutide, with a maximum weight loss of 19.7% after 24 weeks [2][1]. - The safety profile of UBT251 is favorable, with only mild to moderate adverse events primarily related to gastrointestinal issues, indicating potential for better safety compared to retatrutide [3][1]. - The initiation of global Phase II trials for UBT251 by Novo Nordisk is expected to enhance the certainty of overseas sales potential, addressing previous commercialization speed shortcomings [4][1]. Summary by Sections Efficacy of UBT251 - In a Phase II trial involving 205 obese patients with a baseline average BMI of 33.1 kg/m², the treatment groups (2/4/6 mg) showed significant weight loss compared to the placebo group, which only lost 2% [2][1]. - The weight loss rates for UBT251 were superior to those reported for retatrutide in its Phase II trials, which had a baseline average BMI of 37.3 kg/m² [2][1]. Safety Profile - UBT251 demonstrated excellent safety in the Phase II trial, with no adverse events leading to withdrawal, and a lower incidence of gastrointestinal side effects compared to retatrutide [3][1]. Market Potential - UBT251 is positioned as a leading candidate in Novo Nordisk's pipeline, with expectations for it to become a significant commercial product, especially as it addresses a gap in the company's offerings compared to competitors [4][1]. - The report anticipates that UBT251 will enter global Phase III trials in 2027, potentially becoming a blockbuster product for Novo Nordisk [4][1]. Financial Projections - The company’s EPS forecasts for 2025, 2026, and 2027 are projected at 1.28, 1.19, and 1.42 RMB respectively, with a target price set at 20.92 HKD based on a 16x PE ratio for 2026 [5][6].